We serve Chemical Name:(2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid CAS:146664-09-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid
CAS.NO:146664-09-7
Synonyms:N-Acetyl-4-cyanophenylalanine;4-cyano-N-acetyl-D-phenylalanine;D-Phenylalanine,N-acetyl-4-cyano
Molecular Formula:C12H12N2O3
Molecular Weight:232.23500
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:535.138ºC at 760 mmHg
Density:1.276 g/cm3
Index of Refraction:
PSA:90.19000
Exact Mass:232.08500
LogP:1.08098
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like N-Acetyl-4-cyanophenylalanine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,D-Phenylalanine,N-acetyl-4-cyano physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-cyano-N-acetyl-D-phenylalanine Use and application,N-Acetyl-4-cyanophenylalanine technical grade,usp/ep/jp grade.
Related News: What’s the background? (2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid manufacturer It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. (2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid supplier It does not require a production license for the drug substance, and can be produced in an ordinary chemical plant. As long as it reaches a certain level, it can be used for the synthesis of the drug substance. (2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid vendor As you can see, a considerable number of staff is involved in the production phase until an API is finally manufactured. (2R)-2-acetamido-3-(4-cyanophenyl)propanoic acid factory The drug, Imfinzi, when added to chemotherapy and the drugmaker��s other cancer drug tremelimumab, significantly improved the survival of patients without the disease progressing, when compared to chemotherapy alone, the company said.
